# Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

> **NCT01614041** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 274 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Usual dose treatment of Tandospirone
- **DRUG:** Comparative high dose of tandospirone treatment

## Key facts

- **NCT ID:** NCT01614041
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-10
- **Primary completion:** 2018-09-11
- **Final completion:** 2019-07
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614041, "Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01614041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*